Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Momenta's Humira will be a non-starter.
I am hearing that AbbVie dropped the price of Humira in Europe by 80% to combat the biosimilars yet still is able to have a 75% profit margin on the drug.
The US users are taking it on the chin.
Your last comment is spot on.
Ran into a MNTA insider at Fenway last night. CW is out and jbog will be selected as new CEO.
Look for after the bell announcement on Friday.
Would strongly recommend that all board participants buy as many shares as possible as I just sold my remaining holdings.
Earnings report is certainly a misnomer!
I am not surprised regarding the specialty pharma focus as most formularies have placed MS drugs with specialty, with preauth and now even step therapy.
I believe that I mentioned this a couple of years ago, but when Glatopa 20 mg came to market, Sandoz priced the product below $12,000 annually for at least some of the PBMs.
Also, not positive, but believe that Glatopa is the only glatiramer acetate available through Express Scripts, with previous Copxaxone users grandfathered.
Flo,
Have always appreciated your input, yet you edited the last part of the NVS release.
The full release reads, "We've been regularly scanning and looking for bolt-in acquisition candidates, and contrary to Investorshub, they do not include Momenta."
I briefly considered applying but they only offered options for 100,000 shares and mandated a vesting period of 30 days.
Given MNTA's past packages, thought I would hold out for more.
FWIW, stock price just jumped on big volume.
It may take much more time to "hit the shelves" as they likely were not allowed to produce any of the 40 mg prefilled syringes given the Pfizer manufacturing issues. Would defer expert comments to Jbog.
stock price looking stronger at market end. ? good news shortly.
The 2018 Express Scripts High Performance formulary has both Glatopa and glatiramer ( the Mylan product ) listed as preferred agents but Copaxone is not listed.
Pharmaceutical benefits managers will determine what is dispensed given ultimate cost including cost to patient.
One reason is that while a quick approval would clearly help MNTA, as others have stated, with a generic already on the market, the FDA is likely not to be in a rush.
In MNTA's case, the FDA may need further committee meetings prior to giving Glatopa 40 mg its blessing.
Given that there are 30 hours per lawyer of billable time in a day, this works out to less than 39 weeks of work for these 450 attorneys.
Appreciate the link, but MNTA is truly looking at some short to intermediate pain as a stand alone. Again, no short term revenue drivers. M-enox has been non-existent for a few years. Glatopa 20 mg is shrinking. Glatopa 40 mg remains an uncertainty, seemingly not happening until the second half ( have we heard that song before ? ), slow to partner for any m-Humira candidate, which regardless of any partnership is not coming to the market for a few more years and there may be 8 players already in that market. Failed initial Orencia study, one early immunologic study showing decrease in circulating immunoglobulins that may or may not have any positive effect on disease states and likely years away from any approval. Only cash coming in is related to milestone payments which will not keep up with cash burn.
All this, not to mention ongoing legal exposure with AMPH and perhaps others.
I previously sold the majority of my shares, but still hold a small amount, so I hope you are correct, yet I am not holding my breath.
Clearly an interesting situation with MYL partnering several products, but MNTA could perhaps license that science and progress to date as a spin off if MYL is not interested in the entire company. MYL has had a nice ride up since the glatiramer approval and could certainly offer stock in a deal.
At most I would guess anywhere from $19-$25 a share. I am usually wrong on these things.
Whatever you are smoking or med you are using, I want some!
$30-$40 a share ain't going to happen, although I would welcome it.
MNTA appears to have less than 2 years of cash needs on hand. No significantly profitable current product after the Mylan approval and none on the horizon until at least 2021. Even if 40 mg is approved later this year, profits won't come close to meeting quarterly costs.
Clearly embedded with MYL but would have to "sell" its Glatopa franchise, which is unlikely to fetch much. Obvious buyer would be NVS, if they even have an interest in marketing the drug.
Comes down to its cash and any consequential science that they may have that MYL's other partners are lacking.
My comment mainly related that aside from aa early study, which may or may not have any clinical implications out over a week ago, there has been no positive news on the company, and that any Glatopa news has been negative, due to loss of potential profits.
Perhaps further short covering, etc, but aside form some sort of additional partnership, nothing apparently positive on the horizon.
Are people actually interpreting the possibility of a second half of 2018 approval of 40 mg as good news?
I am baffled as to the price action.
Nice uptick today.
Rumor on the Street is that Momenta is taking over Kodak.
I think I saw Wheeler in line at the ATM machine.
European patent expires in 2020, US in 2021.
Not a bad wait time.
I guess that on a positive note, we can always count on selling MNTA in late December to offset gains in other holdings!
Rumor has it that Momenta will be changing its name to Momenta-Crisper/Blockchain.
Wake me up when MNTA files a pre-grant application for printing money.
If this impacts 40 mg Glatopa, then CW failed in his fiduciary responsibility by not disclosing the information when Pfizer was informed. Letter dated 11/27 and would assume that PFE would have disclosed this info immediately to NVS which should have disclosed it to MNTA.
Perhaps another reason for the drop is the success of MYL and Biocon with generic Herceptin, showing to the pharm world that MYL may not need MNTA's technology to get a valuable asset approved by the FDA.
Strongly recommend they compromise and select Mini Crescent Dogs.
So aside form the small uptick today on low volume, what makes anyone think that this cancellation is a positive?
Could be a leaky pipe in the executive washroom, CW may have overslept due to having fun with five Russian hookers, or PFE again failed FDA review, etc.
I was able to hack into the MNTA computer system and access the presentation.
There will only be one slide in the presentation, showing the entire executive suite and BOD treading water.
CW will then offer to answer any questions.
Bring back Rick Shea!
If Synthon/PFE receives FDA approval for glatiramer prior to MNTA/NVS, heads should roll and the courts should be busy!
Thanks to all for the education.
I thought that was "old " news. TEVA not down, so unlikely related to generic AG news. With TEVA not up, but with both MYL and MNTA dropping sharply, particularly MYL, have to believe it may not be glatiramer related. Perhaps related to Mylan internal issues that may adversely affect the MYL/MNTA partnership.
What just suddenly happened to MYL stock price?
Thanks.
The most reliable indicator throughout the years has been Jbog, so would place him at number 1.
Perhaps news leaked that although MNTA was considering adding Harvey Weinstein to the BOD, in the end, and on a split vote, MNTA decided against the addition.
So why are people buying MNTA at these levels?
Does not appear to have any near term, significantly profitable catalyst on an operational basis.
Guess they can sell their share of Glatopa formulations to NVS and then be purchased by MYL.
I may have assumed wrongly twelve years ago that MNTA had a unique characterization platform and knowledge that allowed them to be able to produce near exact replicas of complicated molecules or mixtures. Even if they had that technology, and even if is best in class, clearly others over time have developed their own set of tools to characterize complex compounds to the degree that the FDA feels is reasonably close.
One of MNTA's limitations/challenges is that by the time one of its products attains FDA approval, other companies may have caught up and other pharma has developed alternative therapeutic options such as the oral anticoagulants or oral MS drugs that the public is more likely to accept and wish to take.
They also have several partnerships that lead to conflicting stances. As jbog mentioned. Novartis has Gilenya, so they may drag their feet in supporting Glatopa. Pfizer, the erstwhile Fill and Finish, actually has a dog in the copaxone race and MYL clearly is a partner, yet a competitor.
MNTA has to date chosen certain "drugs" for evaluation with limited market share such as intracoronary LMWH which failed in studies. Also spends way too much time, energy and especially money in pursuing legal battles that perhaps should not have been engaged in the first place. Only one that bore fruit was the SNY patent issues with Lovenox.
Have to wonder how old CW feels about deciding to do a 50% share with their immune globulin partnership given that the present revenue stream is sorely lacking for the company as a whole.
Overall, cannot provide advice on holding your investment, but MNTA either needs to try to sell itself or develop a product that has a long term life expectancy. There is absolutely no credible scientific reason for the FDA not to have approved 40 mg given the two years lead time of a product that had already received approval for the 20 mg formulation. MNTA and NVS should have been prepared for all possible snafus for a process that should have been a cakewalk.
So given this reasoning, would it be reasonable to anticipate that MNTA's approval will be coming within the next 6 months, or does the FDA really not need to designate/address the exclusivity issue until another generic is approved? No harm, no foul.
Rightly or wrongly, I have always followed Ganesh's stock holdings, and particularly any sales, closely. As one of the two company founders, I have generally noted that except for minimal selling under the registered executive stock selling plan that he has kept his holdings generally intact. I have considered this a long term vote of confidence in the company and hope that this is correct.
Interesting that after all these years, they finally wanted him as COO or perhaps he was personally more interested in the scientific side of the company rather than operations.
and CW sold shares last week near the high for the week.
Down $1.07 since his sale.